Literature DB >> 6283540

Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.

A S Bagnara, M S Hershfield.   

Abstract

Loss of ATP accompanying accumulation of dATP has recently been reported to occur in the erythrocytes and lymphoblasts of patients with T lymphocytic leukemia during treatment with deoxycoformycin, an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) that causes the accumulation of deoxyadenosine. We have studied the mechanisms responsible for adenine ribonucleotide depletion in cultured human CEM T lymphoblastoid cells treated with deoxycoformycin and deoxyadenosine. Accumulation of dATP was accompanied by depletion of total soluble adenine ribonucleotides without change in the adenylate energy charge, by the route ATP --> AMP --> IMP --> inosine --> hypoxanthine; conversion of IMP to AMP and de novo purine synthesis were inhibited in these cells. ATP degradation did not occur in a mutant of CEM that was incapable of phosphorylating deoxyadenosine, or in a B cell line with very limited ability to accumulate dATP. We found that dATP and ATP were both able to stimulate markedly the deamination of AMP by lymphoblast AMP deaminase; dAMP was a poor substrate for this enzyme (K(m) = 2.4 mM, vs. 0.4 mM for AMP). Similarly, dATP as well as ATP caused marked activation of IMP dephosphorylation by a lymphoblast cytoplasmic nucleotidase. Inhibition of intracellular AMP deaminase with coformycin prevented degradation of adenine ribonucleotides without affecting dATP accumulation. We propose that ATP-dependent phosphorylation of deoxyadenosine generates ADP and AMP. Simultaneously, dATP accumulation stimulates deamination of AMP, but not dAMP, and the dephosphorylation of IMP to inosine. Coupling of AMP degradation to ATP utilization in deoxyadenosine phosphorylation maintains the adenylate energy charge despite net depletion of cellular ATP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283540      PMCID: PMC346263          DOI: 10.1073/pnas.79.8.2673

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Studies of the regulation of purine nucleotide catabolism.

Authors:  C A Lomax; A S Bagnara; J F Henderson
Journal:  Can J Biochem       Date:  1975-02

2.  Workshop on severe combined immunological deficiency disease and adenosine deaminase deficiency. Albany, New York, on October 1, 1973.

Authors:  R J Pickering; B Pollara; H J Meuwissen
Journal:  Clin Immunol Immunopathol       Date:  1974-11

3.  The deoxyribonucleoside 5'-triphosphate (dATP and dTTP) pool in phytohemagglutinin-stimulated and non-stimulated human lymphocytes.

Authors:  B Munch-Petersen; G Tyrsted; B Dupont
Journal:  Exp Cell Res       Date:  1973-06       Impact factor: 3.905

4.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

5.  Adenosine formation and metabolism during adenosine triphosphate catabolism in Ehrlich ascites tumor cells.

Authors:  C A Lomax; J F Henderson
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

6.  Rate-limiting steps in the interconversion of purine ribonucleotides in Ehrlich ascites tumor cells in vitro.

Authors:  G W Crabtree; J F Henderson
Journal:  Cancer Res       Date:  1971-07       Impact factor: 12.701

7.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

8.  Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors.

Authors:  E C Moore; R B Hurlbert
Journal:  J Biol Chem       Date:  1966-10-25       Impact factor: 5.157

9.  Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point.

Authors:  M S Hershfield; J E Seegmiller
Journal:  J Biol Chem       Date:  1976-12-10       Impact factor: 5.157

10.  Expression of purine overproduction in a series of 8-azaguanine-resistant diploid human lymphoblast lines.

Authors:  J E Lever; G Nuki; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

View more
  5 in total

1.  Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2'-deoxycoformycin and deoxyadenosine.

Authors:  A Begleiter; L Verburg; L G Israels; J B Johnston
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Nucleotide catabolism and nucleoside cycles in human thymocytes. Role of orthophosphate.

Authors:  J Barankiewicz; A Cohen
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

4.  Purine metabolism in Acholeplasma laidlawii B: novel PPi-dependent nucleoside kinase activity.

Authors:  V V Tryon; D Pollack
Journal:  J Bacteriol       Date:  1984-07       Impact factor: 3.490

5.  Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles.

Authors:  F X Arredondo-Vega; I Santisteban; S Daniels; S Toutain; M S Hershfield
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.